Table 2 Indications for infliximab use and concomitant treatment(s)
Variable | N (%) |
|---|---|
Indications for infliximab (may be combined) | |
Previous treatments failure | 35 (64) |
Steroid dependence (≥ 10 mg/day) | 24 (44) |
Adverse events related to previous treatments | 11 (20) |
Recurrence | 11 (20) |
Involved organs that triggered the use of infliximab | |
Central nervous system Multi-systemic Lungs Eye Liver Joints Muscles Peripheral nervous system Other (heart, ear-nose-throat, gut) | 16 (29) 10 (18) 8 (15) 5 (9) 3 (6) 3 (6) 2 (5) 2 (5) 4 (7) |
Concomitant treatments received | |
Infliximab Mean dose (mg/kg) Median interval between two infusions (weeks, IQR) Oral steroids Median dose (mg/day, IQR) Patients who required increased dose at initiation Pulses of methylprednisolone Immunosuppressant Methotrexate Mycophenolate mofetil | 55 (100) 5 5 [4–6] 47 (85) 20 [10–40] 26 (47) 16 (29) 11 (20) 8 (14.5) 3 (5) |